Aegis Capital Reiterates Buy Rating Following Reports of Positive Statin-Vascepa Combo

Loading...
Loading...
In a report published on Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and a price target of $35 on
AmarinAMRN
following reports of a positive Statin-Vascepa combo. In the report, Aegis Capital stated, "This morning, Amarin reported positive data from a Phase 1 clinical trial assessing the pharmacokinetic profile of a fixed-dose combination of the firm's flagship drug product, Vascepa (icosapent ethyl) and a statin (in this case, Crestor or rosuvastatin). This data represents a key cornerstone of Amarin's long- term strategy to eke out a solid market position in the cardiovascular space." Amarin closed on Thursday at $6.30.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsAegis CapitalRaghuram Selvaraju
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...